Durata Therapeutics is currently developing dalbavancin, an intravenous antibiotic product candidate, for the treatment of acute bacterial skin and skin structure infections caused by Gram-positive bacteria. The company aims to reduce hospital stays and overall healthcare costs by offering a once-weekly dosing option for patients. Durata has a team of experienced executives and is actively enrolling patients in global Phase 3 clinical trials for dalbavancin.